Recognized? Gilead partners with five generic drug makers, NIH launches ACTT2 trial

REVIEW: Gilead signed a non-exclusive license agreements with five generic manufacturers in India and Pakistan, will provide Rhett Western Wei 127 national productionAfter this monththe FDA Reid Western Wei (remdesivir) treatment COVID-19 emergency authorization, Gilead (GileadSciences) looking for ways to increase productionRecently, Gilead signed a non-exclusive license agreements with five generic manufacturers in India and Pakistan, will provide Rhett Western Wei 127 national productionhad Gilead by expanding the supply of raw materials, transformation of production lines, the rapid expansion of production and increase the supply capacity of 1.5 million, while in the emergency authorization, Gilead represent 1.5 million of these medicines all donatedthis agreement and Gilead five companies are Mylan (Mylan), Cipla (Cipla), Hee Delong pharmacy (Hetero Labs), jubilant Life Sciences Group (JubilantLifeSciences) and FerozsonsLaboratoriesUnder the agreement, Gilead will share with these five companies, the manufacturing technology, to help them speed up the production of Western Wei Reid, and that each company can own generic pricingGilead said the deal is a "royalty-free" until the World Health Organization announces new crown virus epidemic is no longer a global health crisis, or "until other than Rhett Western Wei drug or vaccine is approved by in the treatment or prevention of a new crown virus, whichever is earlier"
likely to be outsourced to other companies pay a drug produced by Pfizer as well as (Pfizer) and BioNTech, the two companies jointly developed SARS-CoV- for BNT162 2 vaccine, this vaccine in the United States completed its first clinical trial vaccination, in order to cope with large-scale clinical work the next few months, and BioNTech Pfizer is evaluating the need to outsource part of its production of the drug combinationon April 29, Gilead released the data on antiviral therapy for patients with severe coronavirus third stage, on the same day, the US National Institutes of Health (NIH) announced the American Institute of Allergy and Infectious Diseases (NIAID) of the test results, the results of critically ill patients from hospitals in Wuhan 10 clinical trials published in the journal "the lancet." Interestingly, the first two tests achieved positive results, results of clinical trials in China showed no clinical benefit, Gilead said this is because clinical trials in China because of the recruitment of subjects not ended early, so there is no data Statistical significanceJust when everyone waiting for Gilead announced more clinical data in May, some regulators have sit still, such as FDA emergency authorization, the Japanese Ministry of Health, Labor and Welfare (MHLW) approval and the start of a new NIH on Reid Barak Western Wei United erlotinib (Baricitinib) treatment COVID-19 clinical trialEarlier, the co-founder of medicine Chi Li Tianquan network pointed out that from a scientific point of view, the two trials conducted in China and the United States should no longer NIAID to conduct a randomized, double-blind, placebo-controlled trials to confirm the reproducibility of test results by this test result was more convincingWhile the United States has started a project called ACTT2 of iterative testing, a move the United States also made a lot of doctors, scientists expressed dissatisfaction, they think ACTT data only from a preliminary final analysisbut regulators was full of confidence, NIAID director AnthonyS.Fauci said: "We now have conclusive data show that Western Wei Reid shorten the recovery time COVID-19 patients to a certain extent, ACTT2 will check in Reid added Western Wei scheme whether anti-inflammatory drugs can provide additional benefits for patients, including reducing mortality"
Reid Western Wei was once known as the" magic pill ", inadvertently leaked world Health organization data after showed no significant effect for critically ill patients, the clinical study data let a lot of sustained attention to the dynamic circle of partners ignorant, confused, the results of three different data, the data is not even an appropriate control group data, also hope Gilead expanding production at the same time, it can be more comprehensive in-depth study, to achieve the best clinical endpoints, seeking the best drug efficacy latest research six public hospitals in Hong Kong, China as well as researchers at the University of Hong Kong, May 9, published in the "Lancet", a study report shows that interferon β-1b, lopinavir Wei - ritonavir and ribavirin "triple therapy" effective and safe in the treatment of early COVID-19 Kangxi Nuo biological today announced that the National Research Council Canada cooperation, to jointly promote the new type of coronavirus recombinant vaccine (adenovirus vector Ad5-nCoV) clinical trials in Canada The clinical trials from clinical phase I / II began, the goal is to carry out clinical phase III, as quickly demonstrate the clinical efficacy of Ad5-nCoV of protection Reference Source: number of clinical studies GileadinksdealswithgenericsmakerstosupplyCOVID-19therapyremdesivirfor127countries Western Wei Reid announced the results of Sino-US Yin Zhengyi Why? NIHclinicaltrialtestingantiviralremdesivirplusanti-inflammatorydrugbaricitinibforCOVID-19begins Lancet: antiviral interferon β-1b containing a "cocktail" of the new crown disease in patients with mild to a valid Kang Xinuo a biological Announcement editor: Squirtle Disclaimer: This article represents the views only of the author and do not represent the position of drug intellectual network, please share in the comments section to add; For reprint, please be sure to indicate the source and author of the article Related Tags: global , Rhett Western Wei , Gilead Sciences 0 0